$BMRN Headlines BioMarin shares rally as FDA mut
Post# of 89397
Posted On: 12/17/2013 10:12:05 AM
$BMRN Headlines
BioMarin shares rally as FDA mutes criticism of rare disorder drug 5:25 p.m. Nov. 15, 2013 - Russ Britt
German DAX ends at record as Europe stocks rally 11:10 a.m. Sept. 19, 2013 - Sara Sjolin
BioMarin rallies 7.6% on Roche takeover report 5:30 a.m. Sept. 19, 2013 - Sara Sjolin
S&P 500 retests the 50-day moving average 10:07 a.m. Sept. 9, 2013 - Michael Ashbaugh
Biotech ETF's breakout: bullish for stocks overall? 12:11 p.m. Sept. 5, 2013 - blogs.marketwatch.com
Acura, BioMarin mount independent rallies on their own positive news 2:28 p.m. July 1, 2013 - Russ Britt
After the close: Biogen slips, Epizyme slows, BioMarin stalls 4:57 p.m. June 4, 2013 - Russ Britt
Lofty expectations hit BioMarin in development of new cancer drugs 11:56 a.m. June 3, 2013 - Russ Britt
Get out of junk stocks now 12:14 p.m. March 22, 2013 - Mark Hulbert
Charting a slow-motion test of the 2012 peak 11:39 a.m. Jan. 11, 2013 - Michael Ashbaugh
U.S. benchmarks sustain the 2013 breakout 12:00 p.m. Jan. 4, 2013 - Michael Ashbaugh
Meet the S&P 500’s new range 11:17 a.m. Dec. 13, 2012 - Michael Ashbaugh
Charting a lackluster recovery attempt 11:49 a.m. Nov. 21, 2012 - Michael Ashbaugh
‘Aggressive’ comment hits Express Scripts 6:03 p.m. Nov. 5, 2012 - Russ Britt
BioMarin's GALNS meets primary endpoint in trial 9:24 a.m. Nov. 5, 2012 - MarketWatch.com
Biomarin says trial results meet primary endpoint 7:23 a.m. Nov. 5, 2012 - Greg Morcroft
Biomarin says its GALNS Phase III trial posiitve 7:23 a.m. Nov. 5, 2012 - Greg Morcroft
Staking out major support 9:46 a.m. Oct. 3, 2012 - Michael Ashbaugh
Corrective bounce, or sustainable upturn? 10:51 a.m. July 13, 2012 - Michael Ashbaugh
Bears come to life on jobs report 9:14 a.m. July 6, 2012 - Michael Ashbaugh
Insider Trading Alert - GNW, WFC, LII, WDR And BMRN Traded By Insiders 10:30 a.m. Dec. 12, 2013 - TheStreet.com
Orphan Drug Designations: Why You Should Care 10:23 a.m. Dec. 12, 2013 - Seeking Alpha
Myriad, Janssen Partner on BRACAnalysis - Analyst Blog 6:26 p.m. Dec. 10, 2013 - Zacks.com
Cramer's Lightning Round - The Quintessential American Stock That Is Going To Work (12/9/13) 6:01 a.m. Dec. 10, 2013 - Seeking Alpha
'Mad Money' Lightning Round: Get Serious on Sirius 6:00 a.m. Dec. 10, 2013 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: The Rally Rules 8:20 p.m. Dec. 9, 2013 - TheStreet.com
BioMarin Seeks Canadian Approval - Analyst Blog 11:50 a.m. Dec. 5, 2013 - Zacks.com
BioMarin Submits VIMIZIM(TM) (elosulfase alfa) NDS to Health Canada for the Treatment of Morquio A Syndrome Under Priority Review Status 8:00 a.m. Dec. 4, 2013 - CNW Group
BioMarin Pharmaceutical's Management Presents at 2013 Deutsche Bank BioFEST Conference (Transcript) 2:20 p.m. Dec. 3, 2013 - Seeking Alpha
Galena: A Pipeline Rich For Investors 2:46 a.m. Dec. 2, 2013 - Seeking Alpha
Biomarin Pharmaceutical Inc. Stock Upgraded (BMRN) 10:12 a.m. Nov. 29, 2013 - TheStreet.com
UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical on Expected Attractive Returns 10:10 a.m. Nov. 27, 2013 - benzinga.com
Biotech Stock Roundup: EU News Boosts Biogen, Gilead & Celgene - Analyst Blog 10:01 a.m. Nov. 27, 2013 - Zacks.com
2014 FDA Drug Approval Decision Calendar 8:00 a.m. Nov. 27, 2013 - TheStreet.com
UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On BMN-111 Outlook 6:50 a.m. Nov. 27, 2013 - benzinga.com
Myriad, BioMarin Collaborate Again - Analyst Blog 5:05 p.m. Nov. 22, 2013 - Zacks.com
Amicus' 'Transformative" Changes Look More Like Big Step Backward 7:37 p.m. Nov. 20, 2013 - TheStreet.com
Jim Cramer's 6 Stocks in 60 Seconds: DKS COG WDAY BMRN DWRE TSLA (Update 1) 5:09 p.m. Nov. 20, 2013 - TheStreet.com
BioMarin Pharmaceutical Larger Than S&P 500 Component Linear Technology 4:44 p.m. Nov. 20, 2013 - TheStreet.com
Analysts: BioMarin Will Trade Up on Panel Vote and 3 More Research Notes to Browse 3:02 p.m. Nov. 20, 2013 - Wall St. Cheat Sheet
Reports, Positive Results, Updated Clinical Safety and Efficacy Data by Healthcare Companies - Research Report on Johnson & Johnson, Merck, BioMarin, Array BioPharma, and Brookdale Senior Living 8:00 a.m. Dec. 12, 2013 - PR Newswire
Daily Trends Scanner: BioMarin Pharma Inc., Delcath Systems Inc., Akorn Inc., and Insmed Inc. 10:19 a.m. Dec. 11, 2013 - PR Newswire
Stock Price Updates, and Charitable Contributions - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics 8:00 a.m. Dec. 4, 2013 - PR Newswire
Biotech Firms Participate in Upcoming Conferences; Sees Steady Numbers around Thanksgiving - Research Report on BioMarin, Halozyme, PDL BioPharma, Anika Therapeutics, and Exelis 8:00 a.m. Dec. 3, 2013 - PR Newswire
Potential Acquisitions and Stock Price Updates - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics 8:00 a.m. Nov. 26, 2013 - PR Newswire
Dan Spiegelman, CFO of BioMarin, to Present at the Deutsche Bank 2013 BioFest Conference in Boston 5:10 a.m. Nov. 26, 2013 - GlobeNewswire
FDA Approvals, Public Offerings and Stock Price Movements - Research Report on BioMarin, AEterna Zentaris, Charles River, Anika Therapeutics and Halozyme Therapeutics 8:00 a.m. Nov. 25, 2013 - PR Newswire
Drug Milestones, Favorable Ruling, Official Statement, and Quarterly Report - Research Report on BioMarin, Vanda, Cadence, Prana, and Biostar 8:00 a.m. Nov. 20, 2013 - PR Newswire
FDA Advisory Committee Recommends Approval for BioMarin's Vimizim(TM) for the Treatment of Patients With Morquio A Syndrome 5:02 p.m. Nov. 19, 2013 - GlobeNewswire
BioMarin Stock Trading Halted Today 7:10 a.m. Nov. 19, 2013 - GlobeNewswire
FDA Posts Briefing Documents for Advisory Committee Meeting Reviewing Vimizim(TM) for the Treatment of Morquio A Syndrome 9:15 a.m. Nov. 15, 2013 - GlobeNewswire
Pre-Market Review: Delcath Systems Inc., BioMarin Pharma Inc., Insmed Inc., and Akorn Inc. 8:00 a.m. Nov. 15, 2013 - PR Newswire
BioMarin Announces French ATU Granted for Vimizim(TM) for the Treatment of Morquio A Syndrome 7:59 a.m. Nov. 15, 2013 - GlobeNewswire
Clinical Trial Initiations, Conferences Participations, Strategic Collaborations, and Presentation of New Pre-Clinical Data - Research Report on Biogen Idec, BioMarin, Medivation, Cytori, and Alnylam 8:00 a.m. Nov. 8, 2013 - PR Newswire
Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2013 Healthcare Conference 8:30 a.m. Nov. 5, 2013 - GlobeNewswire
Critical Alerts For Citigroup, Community Health, Oracle, Boeing, and BioMarin Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Nov. 1, 2013 - PR Newswire
Biotech Companies Report Quarterly Results - Research Report on Biogen Idec, Alexion, Medivation, BioMarin, and Dyax 9:00 a.m. Oct. 31, 2013 - PR Newswire
BioMarin Initiates Phase 3 Trial for BMN 673 for the Treatment of Metastatic gBRCA Breast Cancer 5:00 a.m. Oct. 31, 2013 - GlobeNewswire
Pre-Market Analysis: BioMarin Pharma Inc., Insmed Inc., Delcath Systems Inc., and Akorn Inc. 11:34 a.m. Oct. 25, 2013 - PR Newswire
BioMarin Announces Third Quarter 2013 Financial Results 5:33 p.m. Oct. 24, 2013 - GlobeNewswire
BioMarin shares rally as FDA mutes criticism of rare disorder drug 5:25 p.m. Nov. 15, 2013 - Russ Britt
German DAX ends at record as Europe stocks rally 11:10 a.m. Sept. 19, 2013 - Sara Sjolin
BioMarin rallies 7.6% on Roche takeover report 5:30 a.m. Sept. 19, 2013 - Sara Sjolin
S&P 500 retests the 50-day moving average 10:07 a.m. Sept. 9, 2013 - Michael Ashbaugh
Biotech ETF's breakout: bullish for stocks overall? 12:11 p.m. Sept. 5, 2013 - blogs.marketwatch.com
Acura, BioMarin mount independent rallies on their own positive news 2:28 p.m. July 1, 2013 - Russ Britt
After the close: Biogen slips, Epizyme slows, BioMarin stalls 4:57 p.m. June 4, 2013 - Russ Britt
Lofty expectations hit BioMarin in development of new cancer drugs 11:56 a.m. June 3, 2013 - Russ Britt
Get out of junk stocks now 12:14 p.m. March 22, 2013 - Mark Hulbert
Charting a slow-motion test of the 2012 peak 11:39 a.m. Jan. 11, 2013 - Michael Ashbaugh
U.S. benchmarks sustain the 2013 breakout 12:00 p.m. Jan. 4, 2013 - Michael Ashbaugh
Meet the S&P 500’s new range 11:17 a.m. Dec. 13, 2012 - Michael Ashbaugh
Charting a lackluster recovery attempt 11:49 a.m. Nov. 21, 2012 - Michael Ashbaugh
‘Aggressive’ comment hits Express Scripts 6:03 p.m. Nov. 5, 2012 - Russ Britt
BioMarin's GALNS meets primary endpoint in trial 9:24 a.m. Nov. 5, 2012 - MarketWatch.com
Biomarin says trial results meet primary endpoint 7:23 a.m. Nov. 5, 2012 - Greg Morcroft
Biomarin says its GALNS Phase III trial posiitve 7:23 a.m. Nov. 5, 2012 - Greg Morcroft
Staking out major support 9:46 a.m. Oct. 3, 2012 - Michael Ashbaugh
Corrective bounce, or sustainable upturn? 10:51 a.m. July 13, 2012 - Michael Ashbaugh
Bears come to life on jobs report 9:14 a.m. July 6, 2012 - Michael Ashbaugh
Insider Trading Alert - GNW, WFC, LII, WDR And BMRN Traded By Insiders 10:30 a.m. Dec. 12, 2013 - TheStreet.com
Orphan Drug Designations: Why You Should Care 10:23 a.m. Dec. 12, 2013 - Seeking Alpha
Myriad, Janssen Partner on BRACAnalysis - Analyst Blog 6:26 p.m. Dec. 10, 2013 - Zacks.com
Cramer's Lightning Round - The Quintessential American Stock That Is Going To Work (12/9/13) 6:01 a.m. Dec. 10, 2013 - Seeking Alpha
'Mad Money' Lightning Round: Get Serious on Sirius 6:00 a.m. Dec. 10, 2013 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: The Rally Rules 8:20 p.m. Dec. 9, 2013 - TheStreet.com
BioMarin Seeks Canadian Approval - Analyst Blog 11:50 a.m. Dec. 5, 2013 - Zacks.com
BioMarin Submits VIMIZIM(TM) (elosulfase alfa) NDS to Health Canada for the Treatment of Morquio A Syndrome Under Priority Review Status 8:00 a.m. Dec. 4, 2013 - CNW Group
BioMarin Pharmaceutical's Management Presents at 2013 Deutsche Bank BioFEST Conference (Transcript) 2:20 p.m. Dec. 3, 2013 - Seeking Alpha
Galena: A Pipeline Rich For Investors 2:46 a.m. Dec. 2, 2013 - Seeking Alpha
Biomarin Pharmaceutical Inc. Stock Upgraded (BMRN) 10:12 a.m. Nov. 29, 2013 - TheStreet.com
UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical on Expected Attractive Returns 10:10 a.m. Nov. 27, 2013 - benzinga.com
Biotech Stock Roundup: EU News Boosts Biogen, Gilead & Celgene - Analyst Blog 10:01 a.m. Nov. 27, 2013 - Zacks.com
2014 FDA Drug Approval Decision Calendar 8:00 a.m. Nov. 27, 2013 - TheStreet.com
UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On BMN-111 Outlook 6:50 a.m. Nov. 27, 2013 - benzinga.com
Myriad, BioMarin Collaborate Again - Analyst Blog 5:05 p.m. Nov. 22, 2013 - Zacks.com
Amicus' 'Transformative" Changes Look More Like Big Step Backward 7:37 p.m. Nov. 20, 2013 - TheStreet.com
Jim Cramer's 6 Stocks in 60 Seconds: DKS COG WDAY BMRN DWRE TSLA (Update 1) 5:09 p.m. Nov. 20, 2013 - TheStreet.com
BioMarin Pharmaceutical Larger Than S&P 500 Component Linear Technology 4:44 p.m. Nov. 20, 2013 - TheStreet.com
Analysts: BioMarin Will Trade Up on Panel Vote and 3 More Research Notes to Browse 3:02 p.m. Nov. 20, 2013 - Wall St. Cheat Sheet
Reports, Positive Results, Updated Clinical Safety and Efficacy Data by Healthcare Companies - Research Report on Johnson & Johnson, Merck, BioMarin, Array BioPharma, and Brookdale Senior Living 8:00 a.m. Dec. 12, 2013 - PR Newswire
Daily Trends Scanner: BioMarin Pharma Inc., Delcath Systems Inc., Akorn Inc., and Insmed Inc. 10:19 a.m. Dec. 11, 2013 - PR Newswire
Stock Price Updates, and Charitable Contributions - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics 8:00 a.m. Dec. 4, 2013 - PR Newswire
Biotech Firms Participate in Upcoming Conferences; Sees Steady Numbers around Thanksgiving - Research Report on BioMarin, Halozyme, PDL BioPharma, Anika Therapeutics, and Exelis 8:00 a.m. Dec. 3, 2013 - PR Newswire
Potential Acquisitions and Stock Price Updates - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics 8:00 a.m. Nov. 26, 2013 - PR Newswire
Dan Spiegelman, CFO of BioMarin, to Present at the Deutsche Bank 2013 BioFest Conference in Boston 5:10 a.m. Nov. 26, 2013 - GlobeNewswire
FDA Approvals, Public Offerings and Stock Price Movements - Research Report on BioMarin, AEterna Zentaris, Charles River, Anika Therapeutics and Halozyme Therapeutics 8:00 a.m. Nov. 25, 2013 - PR Newswire
Drug Milestones, Favorable Ruling, Official Statement, and Quarterly Report - Research Report on BioMarin, Vanda, Cadence, Prana, and Biostar 8:00 a.m. Nov. 20, 2013 - PR Newswire
FDA Advisory Committee Recommends Approval for BioMarin's Vimizim(TM) for the Treatment of Patients With Morquio A Syndrome 5:02 p.m. Nov. 19, 2013 - GlobeNewswire
BioMarin Stock Trading Halted Today 7:10 a.m. Nov. 19, 2013 - GlobeNewswire
FDA Posts Briefing Documents for Advisory Committee Meeting Reviewing Vimizim(TM) for the Treatment of Morquio A Syndrome 9:15 a.m. Nov. 15, 2013 - GlobeNewswire
Pre-Market Review: Delcath Systems Inc., BioMarin Pharma Inc., Insmed Inc., and Akorn Inc. 8:00 a.m. Nov. 15, 2013 - PR Newswire
BioMarin Announces French ATU Granted for Vimizim(TM) for the Treatment of Morquio A Syndrome 7:59 a.m. Nov. 15, 2013 - GlobeNewswire
Clinical Trial Initiations, Conferences Participations, Strategic Collaborations, and Presentation of New Pre-Clinical Data - Research Report on Biogen Idec, BioMarin, Medivation, Cytori, and Alnylam 8:00 a.m. Nov. 8, 2013 - PR Newswire
Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2013 Healthcare Conference 8:30 a.m. Nov. 5, 2013 - GlobeNewswire
Critical Alerts For Citigroup, Community Health, Oracle, Boeing, and BioMarin Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Nov. 1, 2013 - PR Newswire
Biotech Companies Report Quarterly Results - Research Report on Biogen Idec, Alexion, Medivation, BioMarin, and Dyax 9:00 a.m. Oct. 31, 2013 - PR Newswire
BioMarin Initiates Phase 3 Trial for BMN 673 for the Treatment of Metastatic gBRCA Breast Cancer 5:00 a.m. Oct. 31, 2013 - GlobeNewswire
Pre-Market Analysis: BioMarin Pharma Inc., Insmed Inc., Delcath Systems Inc., and Akorn Inc. 11:34 a.m. Oct. 25, 2013 - PR Newswire
BioMarin Announces Third Quarter 2013 Financial Results 5:33 p.m. Oct. 24, 2013 - GlobeNewswire
(0)
(0)